Trulieve Cannabis Corp (TCNNF)

[FUNMAN]

Echelon Wealth Partners Stick to Their Buy Rating for Trulieve Cannabis
Sep 23, 2020 01:25PM ET

https://www.investing.com/news/echelon-wealth-partners-stick-to-their-buy-rating-for-trulieve-cannabis-2305069

Echelon Wealth Partners analyst Andrew Semple reiterated a Buy rating on Trulieve Cannabis (OTC:TCNNF) on Monday, setting a price target of C$36, which is approximately 50.20% above the present share price of $18.01.

Semple expects Trulieve Cannabis to post earnings per share (EPS) of $0.06 for the third quarter of 2020.

The current consensus among 8 TipRanks analysts is for a Strong Buy rating of shares in Trulieve Cannabis, with an average price target of $32.41.

The analysts price targets range from a high of $40 to a low of $26.3.

In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $120.76 million and a net profit of $37.5 million. The company's market cap is $2.04 billion.

According to TipRanks.com, Echelon Wealth Partners analyst Andrew Semple is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 40.8% and a 70.83% success rate.

Trulieve Cannabis Corp. engages in the provision of medical cannabis products. The firm cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. Its products include smokable flower, inhalation, oral, sublingual, topical, inter-nasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.